Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as VASOPRESSIN V1B RECEPTOR ANTAGONIST (SSR149415)
VASOPRESSIN V1B RECEPTOR ANTAGONIST · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Twice daily |
| SSR149415 - 100mg | EXPERIMENTAL | Twice daily |
| SSR149415 - 250mg | EXPERIMENTAL | Twice daily |
| Name | Type | Description |
|---|---|---|
| VASOPRESSIN V1B RECEPTOR ANTAGONIST (SSR149415) | DRUG | Pharmaceutical form: Capsule Route of administration: oral |
| Placebo | DRUG | Pharmaceutical form: Capsule Route of administration: Oral |
Inclusion criteria : * Diagnosis of major depressive disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition-Text Revision (DSM-IV-TR) and the Mini International Neuropsychiatric Interview (MINI) criteria. Exclusion criteria: * Outpatients unwilling to be hos...
Top 20 of 31 competitors
VASOPRESSIN V1B RECEPTOR ANTAGONIST is being developed for Major Depressive Disorder. It is a small molecule in the psychiatry therapeutic area. The program is in Phase 2 clinical development, and the single completed trial enrolled 100 outpatients with Major Depressive Disorder in the United States.
VASOPRESSIN V1B RECEPTOR ANTAGONIST targets AVPR2, AVPR1A, and AVPR1B, which are vasopressin receptor subtypes. It is classified as an agonist against these targets. The compound is a small molecule developed for Major Depressive Disorder.
Sanofi is developing VASOPRESSIN V1B RECEPTOR ANTAGONIST. Sanofi trades under the ticker SNY. The company has advanced the small molecule into Phase 2 testing for Major Depressive Disorder.
VASOPRESSIN V1B RECEPTOR ANTAGONIST is in Phase 2 clinical development for Major Depressive Disorder. It is an investigational agent and has not been approved. The program has one completed Phase 2 trial and no active trials at this time.
VASOPRESSIN V1B RECEPTOR ANTAGONIST has been studied in one completed Phase 2 trial, NCT01606384. The trial evaluated the potential effects of SSR149415 on the hypothalamic-pituitary-adrenal axis in outpatients with Major Depressive Disorder. It was randomized, double-blind, placebo-controlled, and enrolled 100 participants in the United States.
Yes, VASOPRESSIN V1B RECEPTOR ANTAGONIST is also known as SSR149415. Both names refer to the same Sanofi small molecule developed for Major Depressive Disorder. The completed Phase 2 trial NCT01606384 used the SSR149415 designation.